EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC 4.0

Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations

Niccolo Gori, Alvise Sernicola, Elena Ippoliti, Rosa Coppola, Martina Maurelli, Michela Ortoncelli, Claudia Paganini, Ersilia Tolino, Maria Mariano, Ester Del Duca, Gaia Moretta, Vincenzo Panasiti und 9 weitere

Acta Dermato-Venereologica · 2025

DOI: 10.2340/actadv.v105.43523 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Acta Dermato-Venereologica, 2025. Verfasst von Niccolo Gori und 20 weiteren Autor:innen. Beteiligte Einrichtung: Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipa…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dupilumab, the first biologic treatment approved for moderate to severe atopic dermatitis, has completely revolutionized the management of such disease allowing long-term control of its clinical signs and symptoms. Nevertheless, data regarding the safety and effectiveness profile of dupilumab in patients belonging to special populations are scarce. This observational, multicentric study analysed the effectiveness and safety profile of dupilumab over 3 years in the treatment of 70 patients with moderate to severe atopic dermatitis and associated comorbidities such as cancers, renal and liver failure, viral chronic infections, and degenerative and autoimmune neurological disorders. Patients achieved a significant improvement in both physician-assessed and patient-reported outcomes after 16 weeks of treatment, with a continuous therapeutic response maintained throughout the 156-week period. The safety profile was comparable to clinical trials and real-world data involving patients without significant comorbidities. In conclusion, the findings support the safety of dupilumab in managing severe atopic dermatitis in fragile patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicAntibodies, Monoclonal, HumanizedDermatologic AgentsHumansMaleFemaleTreatment OutcomeAdultMiddle AgedSeverity of Illness IndexTime FactorsComorbidityYoung AdultPatient Reported Outcome MeasuresAgedAdolescent

Substanzen

dupilumabAntibodies, Monoclonal, HumanizedDermatologic Agents

Autor:innen und Institutionen

  • Dermatologia, Dipartimento Universitario di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Univ…
  • Dermatology Unit, Department of Medicine (DIMED), University of Padua, Padova, Italy.
  • Dermatologia, Fondazione Policlinico, Universitario Campus Bio-Medico, Roma, Italy.
  • Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.
  • Department of Medical Sciences, Section of Dermatology, University of Turin, Torino, Italy.
  • Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy; Dermatology Unit, Fondazione Policlinico "Tor Vergata", Rome, Italy.

Zitieren

APA

Gori, N., Sernicola, A., Ippoliti, E., Coppola, R., Maurelli, M., Ortoncelli, M., Paganini, C., Tolino, E., Mariano, M., Del Duca, E., Moretta, G., Panasiti, V., Girolomoni, G., Ribero, S., Boeti, L., Bianchi, L., Fargnoli, M. C., Pellacani, G., Pallotta, S., …, & Galluzzo, M. (2025). Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v105.43523

Vancouver

Gori N, Sernicola A, Ippoliti E, Coppola R, Maurelli M, Ortoncelli M, et al. Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations. Acta Dermato-Venereologica. 2025. doi:10.2340/actadv.v105.43523

BibTeX
@article{Gori2025,
  author = {Gori, Niccolo and Sernicola, Alvise and Ippoliti, Elena and Coppola, Rosa and Maurelli, Martina and Ortoncelli, Michela and Paganini, Claudia and Tolino, Ersilia and Mariano, Maria and Del Duca, Ester and Moretta, Gaia and Panasiti, Vincenzo and Girolomoni, Giampiero and Ribero, Simone and Boeti, Luisa and Bianchi, Luca and Fargnoli, Maria Concetta and Pellacani, Giovanni and Pallotta, Sabatino and Peris, Ketty and Galluzzo, Marco},
  title = {Safety and Effectiveness Profile of Dupilumab in the Treatment of Atopic Dermatitis in Special Populations},
  journal = {Acta Dermato-Venereologica},
  year = {2025},
  doi = {10.2340/actadv.v105.43523}
}
Kostenlos starten →